Shares of Dermira, Inc. (NASDAQ:DERM) have been given a consensus recommendation of “Hold” by the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $44.40.

DERM has been the topic of several research analyst reports. Zacks Investment Research lowered shares of Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC restated a “buy” rating and issued a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Mizuho restated a “buy” rating and issued a $43.00 price objective (up from $40.00) on shares of Dermira in a report on Thursday, September 7th. Evercore ISI initiated coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price objective on the stock. Finally, BidaskClub lowered shares of Dermira from a “buy” rating to a “hold” rating in a report on Monday, July 3rd.

COPYRIGHT VIOLATION NOTICE: “Dermira, Inc. (DERM) Receives Consensus Recommendation of “Hold” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/25/dermira-inc-derm-receives-consensus-recommendation-of-hold-from-analysts.html.

In other Dermira news, CEO Thomas G. Wiggans sold 9,500 shares of Dermira stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eugene A. Bauer sold 7,500 shares of Dermira stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,300 shares of company stock valued at $682,651. 13.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ardsley Advisory Partners acquired a new position in Dermira in the 2nd quarter valued at about $291,000. California State Teachers Retirement System grew its position in Dermira by 18.2% in the 2nd quarter. California State Teachers Retirement System now owns 67,518 shares of the biopharmaceutical company’s stock valued at $1,967,000 after acquiring an additional 10,400 shares in the last quarter. Bank of Nova Scotia acquired a new position in Dermira in the 2nd quarter valued at about $318,000. Platinum Investment Management Ltd. grew its position in Dermira by 28.8% in the 2nd quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock valued at $1,681,000 after acquiring an additional 12,900 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Dermira by 51.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,709 shares of the biopharmaceutical company’s stock valued at $866,000 after acquiring an additional 10,110 shares in the last quarter. 97.80% of the stock is owned by institutional investors.

Dermira (DERM) traded down 3.55% on Wednesday, hitting $26.36. 177,783 shares of the stock were exchanged. Dermira has a 52-week low of $21.35 and a 52-week high of $38.75. The stock’s 50 day moving average price is $26.92 and its 200 day moving average price is $28.04. The firm’s market cap is $1.10 billion.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.00 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. Equities research analysts forecast that Dermira will post ($4.20) earnings per share for the current year.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.